nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—ABCG2—Topotecan—peripheral nervous system neoplasm	0.117	0.269	CbGbCtD
Cladribine—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0813	0.187	CbGbCtD
Cladribine—SLC22A2—Cisplatin—peripheral nervous system neoplasm	0.0633	0.145	CbGbCtD
Cladribine—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0501	0.115	CbGbCtD
Cladribine—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0467	0.107	CbGbCtD
Cladribine—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0459	0.105	CbGbCtD
Cladribine—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0313	0.0718	CbGbCtD
Cladribine—PNP—tongue—peripheral nervous system neoplasm	0.00737	0.137	CbGeAlD
Cladribine—RRM2B—ganglion—peripheral nervous system neoplasm	0.00691	0.129	CbGeAlD
Cladribine—RRM2B—trigeminal ganglion—peripheral nervous system neoplasm	0.00339	0.0632	CbGeAlD
Cladribine—POLE3—trigeminal ganglion—peripheral nervous system neoplasm	0.00321	0.0598	CbGeAlD
Cladribine—RRM2B—parotid gland—peripheral nervous system neoplasm	0.0032	0.0596	CbGeAlD
Cladribine—POLE3—parotid gland—peripheral nervous system neoplasm	0.00303	0.0564	CbGeAlD
Cladribine—NR5A1—brainstem—peripheral nervous system neoplasm	0.00275	0.0513	CbGeAlD
Cladribine—POLE—trigeminal ganglion—peripheral nervous system neoplasm	0.00245	0.0456	CbGeAlD
Cladribine—SLC22A1—ganglion—peripheral nervous system neoplasm	0.00226	0.0421	CbGeAlD
Cladribine—POLA1—trigeminal ganglion—peripheral nervous system neoplasm	0.00211	0.0393	CbGeAlD
Cladribine—POLA1—parotid gland—peripheral nervous system neoplasm	0.00199	0.0371	CbGeAlD
Cladribine—RRM1—trigeminal ganglion—peripheral nervous system neoplasm	0.00167	0.0312	CbGeAlD
Cladribine—SLC22A2—trigeminal ganglion—peripheral nervous system neoplasm	0.00157	0.0293	CbGeAlD
Cladribine—RRM2B—cerebellum—peripheral nervous system neoplasm	0.00148	0.0276	CbGeAlD
Cladribine—POLE3—cerebellum—peripheral nervous system neoplasm	0.0014	0.0261	CbGeAlD
Cladribine—NR5A1—cerebellum—peripheral nervous system neoplasm	0.00136	0.0253	CbGeAlD
Cladribine—DCK—trigeminal ganglion—peripheral nervous system neoplasm	0.0013	0.0242	CbGeAlD
Cladribine—DCK—parotid gland—peripheral nervous system neoplasm	0.00123	0.0229	CbGeAlD
Cladribine—POLE2—Teniposide—Etoposide—peripheral nervous system neoplasm	0.00114	0.147	CbGdCrCtD
Cladribine—POLE—cerebellum—peripheral nervous system neoplasm	0.00107	0.0199	CbGeAlD
Cladribine—POLA1—cerebellum—peripheral nervous system neoplasm	0.000921	0.0171	CbGeAlD
Cladribine—RRM2—Vinorelbine—Vincristine—peripheral nervous system neoplasm	0.000906	0.117	CbGdCrCtD
Cladribine—POLA1—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.000857	0.111	CbGdCrCtD
Cladribine—RRM2B—Direct p53 effectors—MET—peripheral nervous system neoplasm	0.000853	0.00656	CbGpPWpGaD
Cladribine—RRM2B—DNA Damage Response—MYC—peripheral nervous system neoplasm	0.000788	0.00605	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—MYC—peripheral nervous system neoplasm	0.000761	0.00585	CbGpPWpGaD
Cladribine—PNP—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000744	0.00572	CbGpPWpGaD
Cladribine—RRM1—cerebellum—peripheral nervous system neoplasm	0.000731	0.0136	CbGeAlD
Cladribine—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000726	0.0135	CbGeAlD
Cladribine—POLE2—G1 to S cell cycle control—CDKN2A—peripheral nervous system neoplasm	0.00071	0.00545	CbGpPWpGaD
Cladribine—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000685	0.0128	CbGeAlD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000672	0.00516	CbGpPWpGaD
Cladribine—RRM2B—DNA Damage Response—TP53—peripheral nervous system neoplasm	0.000647	0.00497	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—peripheral nervous system neoplasm	0.000625	0.0048	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000606	0.00466	CbGpPWpGaD
Cladribine—POLE2—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000594	0.0768	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000594	0.0768	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000594	0.0768	CbGdCrCtD
Cladribine—RRM2B—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00058	0.00445	CbGpPWpGaD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.000574	0.00441	CbGpPWpGaD
Cladribine—DCK—cerebellum—peripheral nervous system neoplasm	0.000568	0.0106	CbGeAlD
Cladribine—POLE2—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.00055	0.0711	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.00055	0.0711	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.00055	0.0711	CbGdCrCtD
Cladribine—RRM1—E2F transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000547	0.0042	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000527	0.00405	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000526	0.00404	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000505	0.00388	CbGpPWpGaD
Cladribine—PNP—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000503	0.00386	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—MYC—peripheral nervous system neoplasm	0.000481	0.0037	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000481	0.00369	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—EED—peripheral nervous system neoplasm	0.000481	0.00369	CbGpPWpGaD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.000473	0.00363	CbGpPWpGaD
Cladribine—PNP—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000459	0.0593	CbGdCrCtD
Cladribine—POLE—G1 to S cell cycle control—CDKN2A—peripheral nervous system neoplasm	0.000458	0.00351	CbGpPWpGaD
Cladribine—RRM2—E2F transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.00045	0.00346	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.00044	0.00338	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000433	0.00333	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000428	0.00328	CbGpPWpGaD
Cladribine—PNP—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000424	0.0549	CbGdCrCtD
Cladribine—NR5A1—Developmental Biology—NCAM1—peripheral nervous system neoplasm	0.00042	0.00322	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GNS—peripheral nervous system neoplasm	0.000419	0.00322	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—CDKN2A—peripheral nervous system neoplasm	0.00041	0.00315	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—NME1—peripheral nervous system neoplasm	0.000402	0.00309	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—peripheral nervous system neoplasm	0.000396	0.00304	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—TP53—peripheral nervous system neoplasm	0.000395	0.00304	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	0.000395	0.00303	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000395	0.00303	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—COX2—peripheral nervous system neoplasm	0.000387	0.00297	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000384	0.00295	CbGpPWpGaD
Cladribine—RRM1—E2F transcription factor network—MYC—peripheral nervous system neoplasm	0.000371	0.00285	CbGpPWpGaD
Cladribine—PNP—Metabolism—GNS—peripheral nervous system neoplasm	0.000364	0.00279	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TP53—peripheral nervous system neoplasm	0.000363	0.00279	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000352	0.0027	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—AURKA—peripheral nervous system neoplasm	0.00035	0.00269	CbGpPWpGaD
Cladribine—PNP—Metabolism—NME1—peripheral nervous system neoplasm	0.000349	0.00268	CbGpPWpGaD
Cladribine—PNP—Metabolism—COX2—peripheral nervous system neoplasm	0.000336	0.00258	CbGpPWpGaD
Cladribine—POLE2—G1/S Transition—MYC—peripheral nervous system neoplasm	0.00033	0.00253	CbGpPWpGaD
Cladribine—DCK—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000329	0.00253	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	0.000324	0.00249	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	0.000322	0.00247	CbGpPWpGaD
Cladribine—ABCG2—cerebellum—peripheral nervous system neoplasm	0.000317	0.0059	CbGeAlD
Cladribine—POLE2—Cell Cycle—AURKA—peripheral nervous system neoplasm	0.000313	0.00241	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—ABCB1—peripheral nervous system neoplasm	0.000312	0.0024	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—MYC—peripheral nervous system neoplasm	0.00031	0.00238	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000308	0.00237	CbGpPWpGaD
Cladribine—RRM2—E2F transcription factor network—MYC—peripheral nervous system neoplasm	0.000305	0.00234	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—BIRC5—peripheral nervous system neoplasm	0.000304	0.00233	CbGpPWpGaD
Cladribine—POLE2—S Phase—MYC—peripheral nervous system neoplasm	0.0003	0.0023	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000297	0.00228	CbGpPWpGaD
Cladribine—RRM1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000289	0.00222	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CHEK2—peripheral nervous system neoplasm	0.00028	0.00215	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—MYC—peripheral nervous system neoplasm	0.000278	0.00214	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—CDKN2A—peripheral nervous system neoplasm	0.000275	0.00212	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000271	0.00208	CbGpPWpGaD
Cladribine—DCK—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000268	0.0346	CbGdCrCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000267	0.00205	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	0.000265	0.00204	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	0.000265	0.00203	CbGpPWpGaD
Cladribine—POLE—Mitotic G1-G1/S phases—CDKN2A—peripheral nervous system neoplasm	0.000264	0.00203	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—TP53—peripheral nervous system neoplasm	0.000255	0.00196	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	0.000255	0.00196	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—ENO2—peripheral nervous system neoplasm	0.000254	0.00195	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000248	0.0019	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	0.000248	0.0019	CbGpPWpGaD
Cladribine—DCK—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.032	CbGdCrCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000244	0.00187	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000242	0.00186	CbGpPWpGaD
Cladribine—RRM2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000238	0.00183	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—AURKA—peripheral nervous system neoplasm	0.000235	0.00181	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—BIRC5—peripheral nervous system neoplasm	0.000227	0.00174	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—AURKA—peripheral nervous system neoplasm	0.000226	0.00173	CbGpPWpGaD
Cladribine—DCK—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000222	0.00171	CbGpPWpGaD
Cladribine—RRM2—G1/S Transition—MYC—peripheral nervous system neoplasm	0.000221	0.0017	CbGpPWpGaD
Cladribine—PNP—Metabolism—ENO2—peripheral nervous system neoplasm	0.00022	0.00169	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.00022	0.00169	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	0.000218	0.00167	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000215	0.00165	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—BCHE—peripheral nervous system neoplasm	0.000215	0.00165	CbGpPWpGaD
Cladribine—POLE—G1/S Transition—MYC—peripheral nervous system neoplasm	0.000213	0.00163	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000211	0.00162	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—AURKA—peripheral nervous system neoplasm	0.00021	0.00161	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	0.000209	0.00161	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GNS—peripheral nervous system neoplasm	0.000209	0.0016	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—MYC—peripheral nervous system neoplasm	0.000209	0.0016	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000205	0.00157	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	0.000204	0.00156	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—BIRC5—peripheral nervous system neoplasm	0.000203	0.00156	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—AURKA—peripheral nervous system neoplasm	0.000202	0.00155	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—TH—peripheral nervous system neoplasm	0.000202	0.00155	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MET—peripheral nervous system neoplasm	0.000201	0.00154	CbGpPWpGaD
Cladribine—RRM1—Metabolism—NME1—peripheral nervous system neoplasm	0.0002	0.00154	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—BIRC5—peripheral nervous system neoplasm	0.000196	0.0015	CbGpPWpGaD
Cladribine—POLE—S Phase—MYC—peripheral nervous system neoplasm	0.000193	0.00148	CbGpPWpGaD
Cladribine—RRM1—Metabolism—COX2—peripheral nervous system neoplasm	0.000193	0.00148	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—CDKN2A—peripheral nervous system neoplasm	0.000188	0.00145	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CHEK2—peripheral nervous system neoplasm	0.000188	0.00144	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—MYC—peripheral nervous system neoplasm	0.000187	0.00143	CbGpPWpGaD
Cladribine—PNP—Metabolism—BCHE—peripheral nervous system neoplasm	0.000186	0.00143	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—PTPN11—peripheral nervous system neoplasm	0.000185	0.00142	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	0.000181	0.00139	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CHEK2—peripheral nervous system neoplasm	0.00018	0.00139	CbGpPWpGaD
Cladribine—POLE—Mitotic G1-G1/S phases—MYC—peripheral nervous system neoplasm	0.000179	0.00138	CbGpPWpGaD
Cladribine—PNP—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000178	0.00136	CbGpPWpGaD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.000177	0.00136	CbGpPWpGaD
Cladribine—PNP—Metabolism—TH—peripheral nervous system neoplasm	0.000175	0.00134	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GNS—peripheral nervous system neoplasm	0.000172	0.00132	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000172	0.00132	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000169	0.0013	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000165	0.000443	CcSEcCtD
Cladribine—RRM2—Metabolism—NME1—peripheral nervous system neoplasm	0.000165	0.00127	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GNAS—peripheral nervous system neoplasm	0.000165	0.00127	CbGpPWpGaD
Cladribine—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000164	0.000441	CcSEcCtD
Cladribine—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000164	0.00044	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000163	0.000438	CcSEcCtD
Cladribine—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000162	0.000436	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000434	CcSEcCtD
Cladribine—RRM2B—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000162	0.00124	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—AURKA—peripheral nervous system neoplasm	0.000161	0.00124	CbGpPWpGaD
Cladribine—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000161	0.000431	CcSEcCtD
Cladribine—DCK—Metabolism—GNS—peripheral nervous system neoplasm	0.000161	0.00123	CbGpPWpGaD
Cladribine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00016	0.000431	CcSEcCtD
Cladribine—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.00016	0.000431	CcSEcCtD
Cladribine—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.00016	0.000428	CcSEcCtD
Cladribine—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.00016	0.000428	CcSEcCtD
Cladribine—Nausea—Topotecan—peripheral nervous system neoplasm	0.00016	0.000428	CcSEcCtD
Cladribine—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000159	0.000427	CcSEcCtD
Cladribine—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000159	0.000427	CcSEcCtD
Cladribine—RRM2—Metabolism—COX2—peripheral nervous system neoplasm	0.000159	0.00122	CbGpPWpGaD
Cladribine—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000426	CcSEcCtD
Cladribine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000158	0.000425	CcSEcCtD
Cladribine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000158	0.000425	CcSEcCtD
Cladribine—SLC22A1—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000157	0.00121	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	0.000157	0.00121	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000157	0.000421	CcSEcCtD
Cladribine—Infection—Etoposide—peripheral nervous system neoplasm	0.000157	0.00042	CcSEcCtD
Cladribine—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.00042	CcSEcCtD
Cladribine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000156	0.000419	CcSEcCtD
Cladribine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000156	0.000419	CcSEcCtD
Cladribine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000154	0.000415	CcSEcCtD
Cladribine—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000154	0.000414	CcSEcCtD
Cladribine—DCK—Metabolism—NME1—peripheral nervous system neoplasm	0.000154	0.00118	CbGpPWpGaD
Cladribine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000154	0.000413	CcSEcCtD
Cladribine—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000413	CcSEcCtD
Cladribine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000154	0.000413	CcSEcCtD
Cladribine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000154	0.000413	CcSEcCtD
Cladribine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000153	0.000412	CcSEcCtD
Cladribine—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000153	0.000411	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—BIRC5—peripheral nervous system neoplasm	0.000152	0.00117	CbGpPWpGaD
Cladribine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000152	0.000409	CcSEcCtD
Cladribine—POLA1—G1/S Transition—MYC—peripheral nervous system neoplasm	0.000151	0.00116	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	0.00015	0.00116	CbGpPWpGaD
Cladribine—Anorexia—Etoposide—peripheral nervous system neoplasm	0.00015	0.000403	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000402	CcSEcCtD
Cladribine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.00015	0.000401	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	0.000149	0.00114	CbGpPWpGaD
Cladribine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000149	0.0004	CcSEcCtD
Cladribine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000149	0.000399	CcSEcCtD
Cladribine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000148	0.000399	CcSEcCtD
Cladribine—DCK—Metabolism—COX2—peripheral nervous system neoplasm	0.000148	0.00114	CbGpPWpGaD
Cladribine—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000396	CcSEcCtD
Cladribine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000147	0.000395	CcSEcCtD
Cladribine—Pain—Cisplatin—peripheral nervous system neoplasm	0.000147	0.000395	CcSEcCtD
Cladribine—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000394	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—ERBB2—peripheral nervous system neoplasm	0.000147	0.00113	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—BIRC5—peripheral nervous system neoplasm	0.000146	0.00112	CbGpPWpGaD
Cladribine—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000145	0.00039	CcSEcCtD
Cladribine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000145	0.000389	CcSEcCtD
Cladribine—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000388	CcSEcCtD
Cladribine—POLA1—Cell Cycle—AURKA—peripheral nervous system neoplasm	0.000144	0.0011	CbGpPWpGaD
Cladribine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000143	0.000385	CcSEcCtD
Cladribine—PNP—Metabolism—GNAS—peripheral nervous system neoplasm	0.000143	0.0011	CbGpPWpGaD
Cladribine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000143	0.000383	CcSEcCtD
Cladribine—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.000382	CcSEcCtD
Cladribine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000142	0.000381	CcSEcCtD
Cladribine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000141	0.00038	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000141	0.00108	CbGpPWpGaD
Cladribine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.00014	0.000377	CcSEcCtD
Cladribine—PNP—Metabolism—ABCB1—peripheral nervous system neoplasm	0.00014	0.00108	CbGpPWpGaD
Cladribine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00014	0.000376	CcSEcCtD
Cladribine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00014	0.000375	CcSEcCtD
Cladribine—POLA1—Mitotic M-M/G1 phases—BIRC5—peripheral nervous system neoplasm	0.000139	0.00107	CbGpPWpGaD
Cladribine—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000374	CcSEcCtD
Cladribine—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000372	CcSEcCtD
Cladribine—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000372	CcSEcCtD
Cladribine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000138	0.000372	CcSEcCtD
Cladribine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000138	0.000371	CcSEcCtD
Cladribine—POLA1—S Phase—MYC—peripheral nervous system neoplasm	0.000138	0.00106	CbGpPWpGaD
Cladribine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000369	CcSEcCtD
Cladribine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000137	0.000369	CcSEcCtD
Cladribine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000137	0.000368	CcSEcCtD
Cladribine—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000366	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000136	0.00105	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—BIRC5—peripheral nervous system neoplasm	0.000136	0.00105	CbGpPWpGaD
Cladribine—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Cladribine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Cladribine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Cladribine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Cladribine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000135	0.000362	CcSEcCtD
Cladribine—Pain—Etoposide—peripheral nervous system neoplasm	0.000135	0.000362	CcSEcCtD
Cladribine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000361	CcSEcCtD
Cladribine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000361	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	0.000135	0.00103	CbGpPWpGaD
Cladribine—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000361	CcSEcCtD
Cladribine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000359	CcSEcCtD
Cladribine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000133	0.000358	CcSEcCtD
Cladribine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000133	0.000357	CcSEcCtD
Cladribine—ABCG2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000132	0.00101	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000352	CcSEcCtD
Cladribine—POLE—Cell Cycle—BIRC5—peripheral nervous system neoplasm	0.000131	0.001	CbGpPWpGaD
Cladribine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000351	CcSEcCtD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000131	0.001	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00013	0.001	CbGpPWpGaD
Cladribine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.00013	0.000349	CcSEcCtD
Cladribine—SLC22A2—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000129	0.000994	CbGpPWpGaD
Cladribine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000129	0.000347	CcSEcCtD
Cladribine—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000346	CcSEcCtD
Cladribine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000129	0.000346	CcSEcCtD
Cladribine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000129	0.000345	CcSEcCtD
Cladribine—POLA1—Cell Cycle—CHEK2—peripheral nervous system neoplasm	0.000129	0.000988	CbGpPWpGaD
Cladribine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000128	0.000345	CcSEcCtD
Cladribine—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000344	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000344	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—MYC—peripheral nervous system neoplasm	0.000128	0.000981	CbGpPWpGaD
Cladribine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000127	0.000342	CcSEcCtD
Cladribine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000127	0.000341	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000341	CcSEcCtD
Cladribine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000127	0.00034	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000127	0.000973	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ENO2—peripheral nervous system neoplasm	0.000127	0.000972	CbGpPWpGaD
Cladribine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000126	0.00034	CcSEcCtD
Cladribine—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000338	CcSEcCtD
Cladribine—SLC22A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000125	0.000963	CbGpPWpGaD
Cladribine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000125	0.000336	CcSEcCtD
Cladribine—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000335	CcSEcCtD
Cladribine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000125	0.000334	CcSEcCtD
Cladribine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000125	0.000334	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000334	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000334	CcSEcCtD
Cladribine—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000334	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000124	0.000951	CbGpPWpGaD
Cladribine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000124	0.000332	CcSEcCtD
Cladribine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000123	0.000331	CcSEcCtD
Cladribine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000331	CcSEcCtD
Cladribine—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000123	0.00033	CcSEcCtD
Cladribine—Rash—Vincristine—peripheral nervous system neoplasm	0.000123	0.000329	CcSEcCtD
Cladribine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000123	0.000329	CcSEcCtD
Cladribine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000329	CcSEcCtD
Cladribine—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000328	CcSEcCtD
Cladribine—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000327	CcSEcCtD
Cladribine—Headache—Vincristine—peripheral nervous system neoplasm	0.000122	0.000327	CcSEcCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000122	0.000935	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000121	0.000933	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000325	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000324	CcSEcCtD
Cladribine—SLC22A1—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000121	0.000926	CbGpPWpGaD
Cladribine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00012	0.000322	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000119	0.000915	CbGpPWpGaD
Cladribine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000118	0.000316	CcSEcCtD
Cladribine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000316	CcSEcCtD
Cladribine—SLC22A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000117	0.000898	CbGpPWpGaD
Cladribine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000312	CcSEcCtD
Cladribine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000116	0.000312	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.00031	CcSEcCtD
Cladribine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000116	0.00031	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000115	0.00031	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000309	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000307	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000305	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000304	CcSEcCtD
Cladribine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000113	0.000304	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000303	CcSEcCtD
Cladribine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000303	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000303	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000301	CcSEcCtD
Cladribine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000301	CcSEcCtD
Cladribine—Chills—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000299	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—NRAS—peripheral nervous system neoplasm	0.000112	0.000857	CbGpPWpGaD
Cladribine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000111	0.000299	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000298	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	0.00011	0.000848	CbGpPWpGaD
Cladribine—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000295	CcSEcCtD
Cladribine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000109	0.000294	CcSEcCtD
Cladribine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000292	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000292	CcSEcCtD
Cladribine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000108	0.000291	CcSEcCtD
Cladribine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000108	0.000291	CcSEcCtD
Cladribine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000291	CcSEcCtD
Cladribine—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000291	CcSEcCtD
Cladribine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000108	0.000289	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000289	CcSEcCtD
Cladribine—RRM1—Metabolism—BCHE—peripheral nervous system neoplasm	0.000107	0.000821	CbGpPWpGaD
Cladribine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000287	CcSEcCtD
Cladribine—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000286	CcSEcCtD
Cladribine—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000281	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.00028	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—BIRC5—peripheral nervous system neoplasm	0.000104	0.000801	CbGpPWpGaD
Cladribine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000104	0.00028	CcSEcCtD
Cladribine—RRM2—Metabolism—ENO2—peripheral nervous system neoplasm	0.000104	0.0008	CbGpPWpGaD
Cladribine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000279	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000278	CcSEcCtD
Cladribine—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000277	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000276	CcSEcCtD
Cladribine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000102	0.000274	CcSEcCtD
Cladribine—RRM1—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000102	0.000783	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	0.000102	0.000783	CbGpPWpGaD
Cladribine—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000273	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	0.000101	0.000776	CbGpPWpGaD
Cladribine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000271	CcSEcCtD
Cladribine—RRM1—Metabolism—TH—peripheral nervous system neoplasm	0.0001	0.000772	CbGpPWpGaD
Cladribine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.0001	0.00027	CcSEcCtD
Cladribine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.0001	0.000269	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000269	CcSEcCtD
Cladribine—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000269	CcSEcCtD
Cladribine—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000269	CcSEcCtD
Cladribine—Rash—Etoposide—peripheral nervous system neoplasm	9.94e-05	0.000267	CcSEcCtD
Cladribine—Dermatitis—Etoposide—peripheral nervous system neoplasm	9.93e-05	0.000266	CcSEcCtD
Cladribine—Headache—Etoposide—peripheral nervous system neoplasm	9.87e-05	0.000265	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	9.87e-05	0.000265	CcSEcCtD
Cladribine—Malaise—Epirubicin—peripheral nervous system neoplasm	9.76e-05	0.000262	CcSEcCtD
Cladribine—DCK—Metabolism—ENO2—peripheral nervous system neoplasm	9.73e-05	0.000748	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	9.7e-05	0.000745	CbGpPWpGaD
Cladribine—Back pain—Doxorubicin—peripheral nervous system neoplasm	9.69e-05	0.00026	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	9.67e-05	0.000743	CbGpPWpGaD
Cladribine—Cough—Epirubicin—peripheral nervous system neoplasm	9.44e-05	0.000254	CcSEcCtD
Cladribine—Nausea—Etoposide—peripheral nervous system neoplasm	9.36e-05	0.000251	CcSEcCtD
Cladribine—POLA1—Cell Cycle—BIRC5—peripheral nervous system neoplasm	9.32e-05	0.000716	CbGpPWpGaD
Cladribine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	9.29e-05	0.000249	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—peripheral nervous system neoplasm	9.26e-05	0.000248	CcSEcCtD
Cladribine—Myalgia—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000247	CcSEcCtD
Cladribine—Chest pain—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000247	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000247	CcSEcCtD
Cladribine—Anxiety—Epirubicin—peripheral nervous system neoplasm	9.18e-05	0.000247	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	9.15e-05	0.000246	CcSEcCtD
Cladribine—POLE2—Cell Cycle—MYC—peripheral nervous system neoplasm	9.12e-05	0.0007	CbGpPWpGaD
Cladribine—Discomfort—Epirubicin—peripheral nervous system neoplasm	9.1e-05	0.000244	CcSEcCtD
Cladribine—RRM2—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	9.03e-05	0.000694	CbGpPWpGaD
Cladribine—Malaise—Doxorubicin—peripheral nervous system neoplasm	9.03e-05	0.000242	CcSEcCtD
Cladribine—Confusional state—Epirubicin—peripheral nervous system neoplasm	8.91e-05	0.000239	CcSEcCtD
Cladribine—ABCG2—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.89e-05	0.000683	CbGpPWpGaD
Cladribine—Oedema—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.000237	CcSEcCtD
Cladribine—RRM2—Metabolism—BCHE—peripheral nervous system neoplasm	8.8e-05	0.000676	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.8e-05	0.000676	CbGpPWpGaD
Cladribine—Infection—Epirubicin—peripheral nervous system neoplasm	8.78e-05	0.000236	CcSEcCtD
Cladribine—Cough—Doxorubicin—peripheral nervous system neoplasm	8.74e-05	0.000235	CcSEcCtD
Cladribine—POLE—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	8.67e-05	0.000666	CbGpPWpGaD
Cladribine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	8.66e-05	0.000233	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	8.65e-05	0.000232	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	8.62e-05	0.000231	CcSEcCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	8.58e-05	0.000659	CbGpPWpGaD
Cladribine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	8.58e-05	0.00023	CcSEcCtD
Cladribine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	8.54e-05	0.000229	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	8.53e-05	0.000229	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	8.53e-05	0.000229	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	8.53e-05	0.000229	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	8.5e-05	0.000228	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	8.47e-05	0.000227	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	8.42e-05	0.000226	CcSEcCtD
Cladribine—Anorexia—Epirubicin—peripheral nervous system neoplasm	8.42e-05	0.000226	CcSEcCtD
Cladribine—RRM2—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.4e-05	0.000645	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TH—peripheral nervous system neoplasm	8.28e-05	0.000636	CbGpPWpGaD
Cladribine—Hypotension—Epirubicin—peripheral nervous system neoplasm	8.25e-05	0.000222	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	8.24e-05	0.000221	CcSEcCtD
Cladribine—DCK—Metabolism—BCHE—peripheral nervous system neoplasm	8.23e-05	0.000632	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.2e-05	0.00063	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GNAS—peripheral nervous system neoplasm	8.2e-05	0.00063	CbGpPWpGaD
Cladribine—Oedema—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.000219	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—HRAS—peripheral nervous system neoplasm	8.16e-05	0.000627	CbGpPWpGaD
Cladribine—Infection—Doxorubicin—peripheral nervous system neoplasm	8.12e-05	0.000218	CcSEcCtD
Cladribine—RRM1—Metabolism—ABCB1—peripheral nervous system neoplasm	8.05e-05	0.000618	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	8.05e-05	0.000216	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	8.02e-05	0.000215	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	8e-05	0.000215	CcSEcCtD
Cladribine—Insomnia—Epirubicin—peripheral nervous system neoplasm	7.99e-05	0.000214	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	7.98e-05	0.000214	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	7.94e-05	0.00061	CbGpPWpGaD
Cladribine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	7.94e-05	0.000213	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	7.93e-05	0.000213	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	7.9e-05	0.000212	CcSEcCtD
Cladribine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	7.88e-05	0.000211	CcSEcCtD
Cladribine—Somnolence—Epirubicin—peripheral nervous system neoplasm	7.85e-05	0.000211	CcSEcCtD
Cladribine—DCK—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.85e-05	0.000603	CbGpPWpGaD
Cladribine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	7.79e-05	0.000209	CcSEcCtD
Cladribine—DCK—Metabolism—TH—peripheral nervous system neoplasm	7.73e-05	0.000594	CbGpPWpGaD
Cladribine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	7.68e-05	0.000206	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	7.64e-05	0.000205	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	7.63e-05	0.000205	CcSEcCtD
Cladribine—Fatigue—Epirubicin—peripheral nervous system neoplasm	7.62e-05	0.000204	CcSEcCtD
Cladribine—Pain—Epirubicin—peripheral nervous system neoplasm	7.55e-05	0.000203	CcSEcCtD
Cladribine—Constipation—Epirubicin—peripheral nervous system neoplasm	7.55e-05	0.000203	CcSEcCtD
Cladribine—POLE2—Cell Cycle—TP53—peripheral nervous system neoplasm	7.49e-05	0.000575	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	7.45e-05	0.0002	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	7.39e-05	0.000198	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	7.34e-05	0.000197	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	7.29e-05	0.000196	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	7.28e-05	0.000195	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	7.27e-05	0.000195	CcSEcCtD
Cladribine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	7.22e-05	0.000194	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—AKT1—peripheral nervous system neoplasm	7.2e-05	0.000553	CbGpPWpGaD
Cladribine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	7.1e-05	0.000191	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.06e-05	0.000189	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	7.05e-05	0.000189	CcSEcCtD
Cladribine—Urticaria—Epirubicin—peripheral nervous system neoplasm	7.02e-05	0.000188	CcSEcCtD
Cladribine—Pain—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000188	CcSEcCtD
Cladribine—Constipation—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000188	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	6.98e-05	0.000187	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	6.98e-05	0.000187	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	6.91e-05	0.000531	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	6.85e-05	0.000526	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GNAS—peripheral nervous system neoplasm	6.76e-05	0.000519	CbGpPWpGaD
Cladribine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	6.74e-05	0.000181	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.71e-05	0.000515	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.7e-05	0.000515	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	6.68e-05	0.000179	CcSEcCtD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.64e-05	0.00051	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.63e-05	0.000509	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	6.57e-05	0.000505	CbGpPWpGaD
Cladribine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	6.51e-05	0.000175	CcSEcCtD
Cladribine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	6.49e-05	0.000174	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	6.46e-05	0.000173	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	6.46e-05	0.000173	CcSEcCtD
Cladribine—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	6.43e-05	0.000494	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GNS—peripheral nervous system neoplasm	6.36e-05	0.000489	CbGpPWpGaD
Cladribine—Asthenia—Epirubicin—peripheral nervous system neoplasm	6.34e-05	0.00017	CcSEcCtD
Cladribine—DCK—Metabolism—GNAS—peripheral nervous system neoplasm	6.31e-05	0.000485	CbGpPWpGaD
Cladribine—Pruritus—Epirubicin—peripheral nervous system neoplasm	6.25e-05	0.000168	CcSEcCtD
Cladribine—DCK—Metabolism—ABCB1—peripheral nervous system neoplasm	6.2e-05	0.000476	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.18e-05	0.000475	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	6.18e-05	0.000474	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	6.16e-05	0.000474	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—peripheral nervous system neoplasm	6.12e-05	0.00047	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NME1—peripheral nervous system neoplasm	6.1e-05	0.000469	CbGpPWpGaD
Cladribine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	6.04e-05	0.000162	CcSEcCtD
Cladribine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000162	CcSEcCtD
Cladribine—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	5.93e-05	0.000456	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GNS—peripheral nervous system neoplasm	5.93e-05	0.000456	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—peripheral nervous system neoplasm	5.88e-05	0.000451	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—COX2—peripheral nervous system neoplasm	5.87e-05	0.000451	CbGpPWpGaD
Cladribine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000157	CcSEcCtD
Cladribine—Dizziness—Epirubicin—peripheral nervous system neoplasm	5.84e-05	0.000157	CcSEcCtD
Cladribine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	5.78e-05	0.000155	CcSEcCtD
Cladribine—SLC22A1—Metabolism—NME1—peripheral nervous system neoplasm	5.69e-05	0.000437	CbGpPWpGaD
Cladribine—Vomiting—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.000151	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	5.59e-05	0.00015	CcSEcCtD
Cladribine—Rash—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.00015	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	5.56e-05	0.000149	CcSEcCtD
Cladribine—Headache—Epirubicin—peripheral nervous system neoplasm	5.53e-05	0.000149	CcSEcCtD
Cladribine—SLC22A1—Metabolism—COX2—peripheral nervous system neoplasm	5.47e-05	0.00042	CbGpPWpGaD
Cladribine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	5.4e-05	0.000145	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.39e-05	0.000414	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.34e-05	0.00041	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—peripheral nervous system neoplasm	5.31e-05	0.000408	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	5.29e-05	0.000407	CbGpPWpGaD
Cladribine—Nausea—Epirubicin—peripheral nervous system neoplasm	5.25e-05	0.000141	CcSEcCtD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	5.24e-05	0.000402	CbGpPWpGaD
Cladribine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.00014	CcSEcCtD
Cladribine—Rash—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000138	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000138	CcSEcCtD
Cladribine—Headache—Doxorubicin—peripheral nervous system neoplasm	5.12e-05	0.000137	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TP53—peripheral nervous system neoplasm	5.03e-05	0.000386	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.98e-05	0.000382	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.88e-05	0.000375	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.85e-05	0.00013	CcSEcCtD
Cladribine—POLE—Cell Cycle—TP53—peripheral nervous system neoplasm	4.83e-05	0.000371	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	4.68e-05	0.00036	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AKT1—peripheral nervous system neoplasm	4.45e-05	0.000342	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—peripheral nervous system neoplasm	4.19e-05	0.000322	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	3.96e-05	0.000304	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	3.9e-05	0.000299	CbGpPWpGaD
Cladribine—PNP—Metabolism—AKT1—peripheral nervous system neoplasm	3.86e-05	0.000296	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO2—peripheral nervous system neoplasm	3.86e-05	0.000296	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	3.69e-05	0.000284	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—AKT1—peripheral nervous system neoplasm	3.69e-05	0.000283	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO2—peripheral nervous system neoplasm	3.59e-05	0.000276	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—peripheral nervous system neoplasm	3.44e-05	0.000264	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	3.29e-05	0.000253	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—BCHE—peripheral nervous system neoplasm	3.26e-05	0.00025	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.14e-05	0.000241	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.11e-05	0.000239	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	3.09e-05	0.000238	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TH—peripheral nervous system neoplasm	3.06e-05	0.000235	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—BCHE—peripheral nervous system neoplasm	3.04e-05	0.000233	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—peripheral nervous system neoplasm	3.04e-05	0.000233	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.9e-05	0.000222	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TH—peripheral nervous system neoplasm	2.85e-05	0.000219	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—peripheral nervous system neoplasm	2.83e-05	0.000217	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	2.53e-05	0.000194	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GNAS—peripheral nervous system neoplasm	2.5e-05	0.000192	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.48e-05	0.00019	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.45e-05	0.000188	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GNAS—peripheral nervous system neoplasm	2.33e-05	0.000179	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.29e-05	0.000176	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AKT1—peripheral nervous system neoplasm	2.21e-05	0.00017	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AKT1—peripheral nervous system neoplasm	1.82e-05	0.00014	CbGpPWpGaD
Cladribine—DCK—Metabolism—AKT1—peripheral nervous system neoplasm	1.7e-05	0.000131	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	6.82e-06	5.24e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKT1—peripheral nervous system neoplasm	6.75e-06	5.18e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKT1—peripheral nervous system neoplasm	6.29e-06	4.83e-05	CbGpPWpGaD
